Skip to main content

Table 6 The sensitivity analysis at 45% sharing rate for cumulative annual cost saving, cost - effectiveness and cost – benefit of SIF in Montreal

From: A cost-benefit/cost-effectiveness analysis of proposed supervised injection facilities in Montreal, Canada

Variables Annual cost of operation Sharing rate # of HIV averted # of HCV averted HIV cost saved HCV cost saved Cost-effectiveness ratio HCV Cost-effectiveness ratio HIV Cost-benefit ratio HCV Cost-benefit ratio HIV
Post SIF $2,182,800 45% 19 115 $1,817,745 $1,858,645 $18,980 $114,884 1.85 1.8
Two SIF $4,365,600 35% 35 214 $3,003,825 $3,155,002 $20,400 $124,731 1.7 1.7
Three SIF $6,548,400 27% 42 256 $2,294,910 $2,448,208 $25,580 $155,914 1.4 1.4
Four SIF $8,731,200 23% 49 299 $1,585,995 $1,776,557 $29,201 $178,188 1.2 1.2
Five SIF $10,914,000 20% 56 341 $877,080 $1,069,763 $32,006 $194,893 1.1 1.1
Six SIF $13,096,800 16.00% 63 384 $168,165 $398,112 $34,106 $207,886 1 1
Seven SIF $15,279,600 12% 70 427 -$540,750 -$273,539 $35,784 $218,280 0.96 0.98
Average $8,731,200 9% 48 291 $1,375,440 $1,495,413 $30,004 $181,900 1.16 1.17